Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins

Full text
Author(s):
Show less -
Sahm, Bianca Del B. [1] ; Peres, Jade [2] ; Rezende-Teixeira, Paula [1] ; Santos, Evelyne A. [3] ; Branco, Paola C. [1] ; Bauermeister, Anelize [4, 1] ; Kimani, Serah [2] ; Moreira, Eduarda A. [4] ; Bisi-Alves, Renata [3] ; Bellis, Claire [2] ; Mlaza, Mihlali [2] ; Jimenez, Paula C. [5] ; Lopes, Norberto P. [4] ; Machado-Santelli, Glaucia M. [3] ; Prince, Sharon [1, 2] ; Costa-Lotufo, V, Leticia
Total Authors: 16
Affiliation:
[1] V, Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo - Brazil
[2] Univ Cape Town, Dept Human Biol, Div Cell Biol, Cape Town - South Africa
[3] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo - Brazil
[4] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Phys & Chem, Ribeirao Preto - Brazil
[5] Univ Fed Sao Paulo, Dept Sea Sci, Santos - Brazil
Total Affiliations: 5
Document type: Journal article
Source: FRONTIERS IN CHEMISTRY; v. 8, MAR 3 2020.
Web of Science Citations: 0
Abstract

The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences, TBX2 has been considered as a potential target for new anticancer therapies. There has therefore been a substantial interest to identify molecules with TBX2-modulatory activity, but no such substance has been found to date. Here, we adopt a targeted approach based on a reverse-affinity procedure to identify the ability of chromomycins A(5) (CA(5)) and A(6) (CA(6)) to interact with TBX2. Briefly, a TBX2-DNA-binding domain recombinant protein was N-terminally linked to a resin, which in turn, was incubated with either CA(5) or CA(6). After elution, bound material was analyzed by UPLC-MS and CA(5) was recovered from TBX2-loaded resins. To confirm and quantify the affinity (K-D) between the compounds and TBX2, microscale thermophoresis analysis was performed. CA(5) and CA(6) modified the thermophoretic behavior of TBX2, with a K-D in micromolar range. To begin to understand whether these compounds exerted their anti-cancer activity through binding TBX2, we next analyzed their cytotoxicity in TBX2 expressing breast carcinoma, melanoma and rhabdomyosarcoma cells. The results show that CA(5) was consistently more potent than CA(6) in all tested cell lines with IC50 values in the nM range. Of the cancer cell types tested, the melanoma cells were most sensitive. The knockdown of TBX2 in 501mel melanoma cells increased their sensitivity to CA(5) by up to 5 times. Furthermore, inducible expression of TBX2 in 501mel cells genetically engineered to express TBX2 in the presence of doxycycline, were less sensitive to CA(5) than the control cells. Together, the data presented in this study suggest that, in addition to its already recognized DNA-binding properties, CA(5) may be binding the transcription factor TBX2, and it can contribute to its cytotoxic activity. (AU)

FAPESP's process: 18/24865-4 - New approaches in metabolomics: 3D Molecular cartography of ascidians based on LC-MS/MS data
Grantee:Anelize Bauermeister
Support type: Scholarships abroad - Research Internship - Post-doctor
FAPESP's process: 15/17177-6 - Integrative approach on the sustainable prospection of marine natural products: from diversity to anticancer compounds
Grantee:Leticia Veras Costa Lotufo
Support type: BIOTA-FAPESP Program - Thematic Grants
FAPESP's process: 19/02008-5 - Marine compounds that induce DNA damage and inhibit TBX2 as a new strategy to treat breast cancer
Grantee:Leticia Veras Costa Lotufo
Support type: Research Grants - Visiting Researcher Grant - International
FAPESP's process: 18/08400-1 - Marine compounds that induce DNA damage and inhibit TBX2 as a new strategy to treat breast cancer
Grantee:Leticia Veras Costa Lotufo
Support type: Regular Research Grants
FAPESP's process: 17/09022-8 - Inhibitory Apoptosis Proteins (IAPs) as therapeutic targets in melanoma: studies with prodiginines in vemurafenibe-resistant cells
Grantee:Paola Cristina Branco
Support type: Scholarships in Brazil - Post-Doctorate